SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation.

Liu, Y; Chen, J-B; Zhang, M; Zhang, X-L; Meng, J-L; Zhou, J; Hao, Z-Y; Zhang, L; Zu, X-B; Liang, C-Z

Liu, Y; Chen, J-B; Zhang, M; Zhang, X-L; Meng, J-L; Zhou, J; Hao, Z-Y; Zhang, L; Zu, X-B; Liang, C-Z.

Affiliation

Liu Y; Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. liang_chaozhao@ahmu.edu.cn.

Eur Rev Med Pharmacol Sci ; 23(7): 2756-2767, 2019 Apr.

Article in En | MEDLINE | ID: mdl-31002126

Subject(s)

Carcinoma, Renal Cell/metabolism; Immediate-Early Proteins/metabolism; Kidney Neoplasms/pathology; Protein Serine-Threonine Kinases/metabolism; Up-Regulation; Cell Line, Tumor/metabolism; Disease Progression; Extracellular Signal-Regulated MAP Kinases/metabolism; Female; Guanosine Triphosphate/metabolism; Humans; MAP Kinase Signaling System; Male; Phosphorylation; Proto-Oncogene Proteins c-akt/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Up-Regulation / Protein Serine-Threonine Kinases / Immediate-Early Proteins / Kidney Neoplasms Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Eur Rev Med Pharmacol Sci Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2019 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google